Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to PAPP-A: nuchal translucency
PAPP-APregnancy-Associated Plasma Protein A
References in periodicals archive ?
56The origin of the preeclampsia is believed to be lying in the placenta hence many investigators hypothesized a relationship between the PAPP-A levels and preeclampsia.
We sought to assess the multiple biomarker approach using MPO, PAPP-A and hs CRP for the diagnosis and risk stratification of patients with SCAD.
A benchmark estimate of laboratory performance comes from comparing the results of 24 pools of patient samples distributed during the past 3 years and obtained from 36 synthetic samples (only 29 of these samples could be used for the PAPP-A analysis because of the stability issues described later).
PIGF is considered to be a marker, and PAPP-A is considered to be a potential marker, of atherosclerotic plaque instability2, 3.
PAPP-A was measured in serum by using a 1-step enzyme immunoassay based on electrochemiluminescence technology (Elecsys 2010, Roche Diagnostics).
To date, more than 70,000 patients have undergone first-trimester screening using the combination of nuchal translucency free [beta]-HCG, and PAPP-A.
Nuchal Translucency (NT) ultrasound measurements were combined with freeBeta hCG and PAPP-A blood proteins tests.
In all 3 trisomies, increased maternal age, increased NT, and decreased concentration of PAPP-A are observed; however, hCG[beta] concentration is decreased in T13 and T18 but increased in T21.
High levels of free [beta]-HCG and PAPP-A (95th percentile or higher) were not associated with an increased risk in any of the outcomes.
NT screening combined with PAPP-A and free [beta]-HCG yielded a screen positive rate of 4.
First Trimester Screening combines a Nuchal Translucency (NT) measurement of fluid at the back of the fetus' neck and free Beta hCG and PAPP-A dried maternal blood tests to generate a patient-specific risk for Down syndrome and trisomy 18 chromosomal abnormalities.